Webinar
/
March 23, 2022

Conversations with Colin: an interview with Dr. Brad Karlin

Webinar
/
This is some text inside of a div block.

During this session, Colin will interview Dr. Brad Karlin, Highmark Health VP and Executive Medical Director, Behavioral Health, Johns Hopkins University Adjunct Professor, Department of Mental Health, School of Public Health & Past President of the Society of Clinical Psychology.

The two will discuss the current mental health crisis and key needs and opportunities for changing how mental health care is delivered to improve access and quality.

‍

Copy Link

Watch the replay

Here’s our latest

Tackling Reliance on Z-Drugs: providing digital treatments for insomnia

Dr. Dimitri Gavriloff, Clinical Psychologist and Sleep Medicine Specialist, discusses how to tackle the over prescription of Z-drugs, and the digital treatments available for insomnia and sleep problems. Dr. Gavriloff sheds light on the following topics: The core role of sleep for health and function The Three P’s model of insomnia Sleep hygiene Digital CBT...

Webinar
Both Sides of the Coin: Communicating the Impact of Mental Health Equity & ROI

With nearly half of adult Americans experiencing a clinical mental health issue over the past year, it’s clear we need innovative and effective mental health resources to reach people in need. But providing mental health solutions goes far beyond just checking a box, it is paramount to communicate the importance of providing proven mental health...

Webinar
The state of women in the workplace hangs in the balance

Women face an array of unique stressors — many of which have been compounded by the COVID-19 pandemic. This reality has led to women experiencing higher rates of burnout than their male colleagues. And as a result, women are leaving the workforce at record rates. Fortunately, employers have the incredible power to chip away at,...

Webinar

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023